Javascript must be enabled to continue!
Growth defect of domain III glycoprotein B mutants of human cytomegalovirus reverted by compensatory mutations co-localizing in post-fusion conformation
View through CrossRef
AbstractCell entry is a crucial step for a virus to infect a host cell. Human cytomegalovirus (HCMV) utilizes the glycoprotein B (gB) to fuse the viral and host cell membrane upon receptor binding of gH/gL-containing complexes. Fusion is mediated by major conformational changes of gB from a metastable pre-fusion to a stable post-fusion whereby the central trimeric coiled-coils, formed by domain (D) III α helices, remain structurally nearly unchanged. To better understand the role of the stable core, we individually introduced three potentially helix-breaking and one disulfide bond-breaking mutation in the DIII α3 to alter the gB stability, and studied different aspects of the viral behavior upon long-term culturing. Two of the three helix-breaking mutations were lethal for the virus in either fibroblasts or epithelial cells and the third substitution led from mild to severe effects on viral replication and infection efficiency. gB_Y494P and gB_I495P suggest that the pre-fusion conformation was stabilized and the fusion process inhibited, gB_G493P on the other hand displayed a delayed replication increase and spread, more pronounced in epithelial cells, hinting at an impaired fusion. Interestingely, the disulfide bond-breaker mutation, gB_C507S, performed strikingly different in the two cell types – lethal in epithelial cells and an atypical phenotype in fibroblasts, respectively. Replication curve analyses paired with the infection efficiency and the spread morphology suggest a dysregulated fusion process which could be reverted by second-site mutations mapping predominantly to gB DV. This underlines the functional importance of a stable core for a well-regulated DV rearrangement during fusion.ImportanceHuman cytomegalovirus (HCMV) can establish a lifelong infection. In most people, the infection follows an asymptomatic course, however it is a major cause of morbidity and mortality in immunocompromised patients or neonates. HCMV has a very broad cell tropism, ranging from fibroblasts to epi- and endothelial cells. It uses different entry pathways utilizing the core fusion machinery consisting of glycoprotein complexes gH/gL and gB. The fusion protein gB undergoes severe rearrangements from a metastable pre-fusion to a stable post-fusion. Here, we were able to characterize the viral behavior after the introduction of four single point mutations in gBs central core. These led to various cell type-specific atypical phenotypes and the emergence of compensatory mutations, demonstrating an important interaction between domains III and V. We provide a new basis for the delevopment of recombinant stable pre-fusion gB which can further serve as a tool for the drug and vaccine development.
Cold Spring Harbor Laboratory
Title: Growth defect of domain III glycoprotein B mutants of human cytomegalovirus reverted by compensatory mutations co-localizing in post-fusion conformation
Description:
AbstractCell entry is a crucial step for a virus to infect a host cell.
Human cytomegalovirus (HCMV) utilizes the glycoprotein B (gB) to fuse the viral and host cell membrane upon receptor binding of gH/gL-containing complexes.
Fusion is mediated by major conformational changes of gB from a metastable pre-fusion to a stable post-fusion whereby the central trimeric coiled-coils, formed by domain (D) III α helices, remain structurally nearly unchanged.
To better understand the role of the stable core, we individually introduced three potentially helix-breaking and one disulfide bond-breaking mutation in the DIII α3 to alter the gB stability, and studied different aspects of the viral behavior upon long-term culturing.
Two of the three helix-breaking mutations were lethal for the virus in either fibroblasts or epithelial cells and the third substitution led from mild to severe effects on viral replication and infection efficiency.
gB_Y494P and gB_I495P suggest that the pre-fusion conformation was stabilized and the fusion process inhibited, gB_G493P on the other hand displayed a delayed replication increase and spread, more pronounced in epithelial cells, hinting at an impaired fusion.
Interestingely, the disulfide bond-breaker mutation, gB_C507S, performed strikingly different in the two cell types – lethal in epithelial cells and an atypical phenotype in fibroblasts, respectively.
Replication curve analyses paired with the infection efficiency and the spread morphology suggest a dysregulated fusion process which could be reverted by second-site mutations mapping predominantly to gB DV.
This underlines the functional importance of a stable core for a well-regulated DV rearrangement during fusion.
ImportanceHuman cytomegalovirus (HCMV) can establish a lifelong infection.
In most people, the infection follows an asymptomatic course, however it is a major cause of morbidity and mortality in immunocompromised patients or neonates.
HCMV has a very broad cell tropism, ranging from fibroblasts to epi- and endothelial cells.
It uses different entry pathways utilizing the core fusion machinery consisting of glycoprotein complexes gH/gL and gB.
The fusion protein gB undergoes severe rearrangements from a metastable pre-fusion to a stable post-fusion.
Here, we were able to characterize the viral behavior after the introduction of four single point mutations in gBs central core.
These led to various cell type-specific atypical phenotypes and the emergence of compensatory mutations, demonstrating an important interaction between domains III and V.
We provide a new basis for the delevopment of recombinant stable pre-fusion gB which can further serve as a tool for the drug and vaccine development.
Related Results
The Nuclear Fusion Award
The Nuclear Fusion Award
The Nuclear Fusion Award ceremony for 2009 and 2010 award winners was held during the 23rd IAEA Fusion Energy Conference in Daejeon. This time, both 2009 and 2010 award winners w...
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Abstract
Background: Imetelstat, a first in class specific telomerase inhibitor, induced hematologic responses in all patients (pts) with essential thrombocythemia (...
Nfkbiz 3′ UTR Mutations Confer Selective Growth Advantage and Affect Drug Response in Diffuse Large B-Cell Lymphoma
Nfkbiz 3′ UTR Mutations Confer Selective Growth Advantage and Affect Drug Response in Diffuse Large B-Cell Lymphoma
Introduction: The activated B-cell-like (ABC) molecular subgroup of diffuse large B-cell lymphoma (DLBCL) is characterized by activation of NF-κB signaling and increased mortality....
Distinct Profile of FLT3 Mutations in Brazil.
Distinct Profile of FLT3 Mutations in Brazil.
Abstract
Mutations in the tyrosine kinase receptor FLT3 are the most common molecular abnormality in acute myeloid leukemia (AML) being detected in about 30% of AML ...
Small Subclones Harboring NOTCH1, SF3B1 or BIRC3 Mutations Are Clinically Irrelevant in Chronic Lymphocytic Leukemia
Small Subclones Harboring NOTCH1, SF3B1 or BIRC3 Mutations Are Clinically Irrelevant in Chronic Lymphocytic Leukemia
Abstract
Introduction. Ultra-deep next generation sequencing (NGS) allows sensitive detection of mutations and estimation of their clonal abundance in tumor cell pop...
Characterization of nonattaching mutants of Agrobacterium tumefaciens
Characterization of nonattaching mutants of Agrobacterium tumefaciens
The first step in tumor formation by Agrobacterium tumefaciens is the site-specific binding of the bacteria to plant host cells. Transposon mutants of the bacteria which fail to at...
Nonproliferation and fusion power plants
Nonproliferation and fusion power plants
Abstract
The world now appears to be on the brink of realizing commercial fusion. As fusion energy progresses towards near-term commercial deployment, the question arises a...
Leflunomide therapy for refractory cytomegalovirus infections in hematopoietic stem cell transplant recipients
Leflunomide therapy for refractory cytomegalovirus infections in hematopoietic stem cell transplant recipients
Background Currently, there are no prospective, randomized trials analyzing leflunomide for the treatment of cytomegalovirus infection or disease in allogeneic stem cell transplant...


